Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Overview of attention for article published in New England Journal of Medicine, September 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 43 news outlets
blogs: 13 blogs
policy: 6 policy sources
twitter: 911 X users
patent: 6 patents

peer_reviews: 1 peer review site
facebook: 15 Facebook pages
wikipedia: 2 Wikipedia pages
reddit: 2 Redditors
f1000: 1 research highlight platform

Citations

dimensions_citation: 4357 Dimensions

Readers on

mendeley: 1435 Mendeley

Summary News Blogs Policy documents X Patents Peer reviews Facebook Wikipedia Reddit Research highlights Dimensions citations

So far, Altmetric has seen 2 Reddit threads by 2 users.

The DAPA-HF Trial is in: Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction

User GuessableSevens, in the /r/medicine: a subreddit for medical professionals subreddit, 25 Nov 2019

Dapagliflozin reduces worsening heart failure and cardiovascular death in non-diabetic HFrEF patients. DAPA-HF Trial

User Pharm4747, in the /r/medicine: a subreddit for medical professionals subreddit, 24 Sep 2019

This page shows the most recent Reddit threads that mention this research output.

Click here to find out how to access more activity.